Wyeth (WYE) is in the Pharma Industry

• Sort by
• View by Content Type

• Wyeth Profit Hurt By Generics

  NEW YORK (Reuters) - Wyeth WYE posted slightly lower first-quarter earnings on Tuesday, hurt by the recent launch of generic forms of its Protonix ulcer drug, but surprisingly strong sales of other medicines enabled the company to beat Wall Street profit...

  News items 2008-04-22

  Tags: Sales strategy, Sales force management, Wyeth, pharmaceutical company, sales, earnings, New York, Thomson Reuters Corp., revenue, Sun Microsystems Inc., U.S., asset

• Lilly Profit Falls Short, Shares Slump

  By Ransdell Pierson NEW YORK (Reuters) - Eli Lilly and Co LLY on Monday posted lower-than-expected quarterly earnings, as disappointing sales of its Byetta diabetes drug overshadowed growing demand for its other medicines, sending shares 3.4 percent lower. The Indianapolis-based drugmaker earned $1.06...

  News items 2008-04-21

  Tags: Sales strategy, Sales force management, Eli Lilly & Co., foreign-exchange, earnings, Thomson Reuters Corp., sales, chemicals, profit margin, New York, CEO, partnership, tax, acquisition, benefit

• Working With Wyeth to Establish a High-Performance Drug Discovery Capability

  Wyeth is one of the world's largest research driven pharmaceutical and health care products companies. The company wanted to improve its clinical data management capabilities to generate a better performance in its drug development processes. Accenture quickly set out to work with Wyeth to establish a first-of-its-kind business process outsourcing...

  Case studies

  Tags: Vertical industries, Benefits, HEALTHCARE, Accenture Ltd., Wyeth, health care, BPO, data management, high-performance, business process, performance

Additional Resources

• Birkman Method® Helps Pharma Reps Find New Jobs

  HOUSTON -- Eight of the world's largest drug makers recently announced the loss of 42,000 jobs, including such household names as Pfizer and Wyeth. The job losses fell disproportionately on their U.S. sales forces. Clearly, the days of growth for drug sales reps are seemingly over. With unprecedented...

  Articles 2008-05-05

• Public asked about impact of plan for W. Chester site

  The company that wants to develop West Chester's Wyeth-Ayerst property held a public meeting Wednesday to ask people how they felt about the project and its impact on the vibrant business district. The Pennsylvania Real Estate Investment Trust gave the audience at the Chester County Historical Society a questionnaire, with...

  Articles 2008-05-04

• Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey

  LONG BRANCH, N.J., May 2 /PRNewswire/ -- The organizers of Pharma ChemOutsourcing Conference & Exhibition have unveiled this year's extraordinary assembly of pharmaceutical and biotech company speakers who will gather in September. Interest has reached a new peak around the exploding chemical outsourcing activities reshaping R & D...

  Articles 2008-05-02

• Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement

  - Mikael Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research - MADISON, N.J., April 30 /PRNewswire-FirstCall/ -- Wyeth today announced that Robert R. Ruffolo, Jr., Ph.D., 58, will retire as President, Wyeth Research and Senior Vice President, Wyeth, later this year. He will be...

  Articles 2008-04-30

• Wyeth to Present at the Morgan Stanley Global Healthcare Unplugged Conference

  MADISON, N.J., April 30 /PRNewswire-FirstCall/ -- Wyeth announced today that it will present at the Morgan Stanley Global Healthcare Unplugged Conference at 10:30 a.m. Eastern Time today. Presenting for Wyeth will be James Connolly, Executive Vice President and General Manager, Vaccines Business Unit, Wyeth Pharmaceuticals. ...

  Articles 2008-04-30

• Progenics and Wyeth Announce FDA Has Approved RELISTOR

  First Drug for Opioid-Induced Constipation to Launch in United States TARRYTOWN, N.Y. & COLLEGEVILLE, Pa. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration FDA has approved RELISTOR[TM] methylnaltrexone bromide subcutaneous injection for...

  Articles 2008-04-25

• Progenics Board Approves $15 Million Share Repurchase Program

  TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its Board of Directors has approved a share repurchase program to acquire up to $15 million of its outstanding common shares. Funding for the repurchase program will come from the $15 million milestone payment Progenics will receive...

  Articles 2008-04-24

• Wyeth Chairman Robert Essner Announces June 27 Retirement

  - Bernard Poussot to Become Chairman of the Board - MADISON, N.J., April 24 /PRNewswire-FirstCall/ -- Wyeth today announced that its Chairman, Robert Essner, 60, has decided to retire from the Company effective June 27, 2008. Mr. Essner has held the position of Chairman since...

  Articles 2008-04-24

• Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients

  Final Decision from European Commission Expected by Mid-2008 COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., April 24 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc. , today announced that the companies have received a positive opinion for RELISTORTM methylnaltrexone bromide subcutaneous injection from the...

  Articles 2008-04-24

• Wyeth Holds Annual Meeting of Stockholders

  - Stockholders Ratify Board Members, Elect New Member to Board, Reject Stockholder Proposals - - Board Declares Common and Preferred Stock Dividends - MADISON, N.J., April 24 /PRNewswire-FirstCall/ -- At today's Annual Meeting of Stockholders of Wyeth , it was reported that stockholders had re-elected...

  Articles 2008-04-24

• Progenics and Wyeth Announce FDA Has Approved RELISTOR

  First Drug for Opioid-Induced Constipation to Launch in United States TARRYTOWN, N.Y. & COLLEGEVILLE, Pa. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration FDA has approved RELISTOR[TM] methylnaltrexone bromide subcutaneous injection for...

  Articles 2008-04-24

• Market Alert: UDTT Is Still on the Move!

  Wall Street Press Wire( www.WallStreetPressWire.com ) is please to highlight its "stocks on themove" for Tuesday. Our list includes: Universal Detection Technology(OTCBB: UDTT), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Wyeth (NYSE: WYE) and Lockheed Martin Corporation (NYSE: LMT). Wall Street Press Wire is continuing its in-depth coverage of UniversalDetection Technology (OTCBB:...

  Articles 2008-04-23

• More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL

  Wyeth Withdraws European Application COLLEGEVILLE, Pa., April 23 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that it is withdrawing its application for an extension to the European Marketing Authorization for TYGACILR tigecycline. This extension sought approval of TYGACIL for the treatment of...

  Articles 2008-04-23

• Wyeth Reports Earnings Results for the 2008 First Quarter

  - 2008 First Quarter Worldwide Net Revenue Increased 6% to $5.7 Billion and Reported Diluted Earnings per Share Decreased 3% to $0.89. Diluted Earnings per Share, Before Certain Significant Items, was $0.94, equivalent to the $0.94 in the 2007 First Quarter - Reaffirms Full Year Pro Forma Diluted...

  Articles 2008-04-22

• Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis

  First Patient Dosed in Phase 1 Trial of SBI-087, Trubion's Next-Generation Candidate SEATTLE, April 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth , has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate...

  Articles 2008-04-21

• Seven Summits Research Releases Comments on MCD, T, WYE, FCX and PEP

  CHICAGO, April 21 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to: http://www.iotogo.com/StocksToWatch) provides investors with essential information on stocks that may be poised for a significant move. By featuring hedged...

  Articles 2008-04-21

• Hot Stock to Watch - MIHS! April 18, 2008

  Stock Market Alerts' performance stock listincludes: Medical Institutional Services Holdings Incorporated (PINKSHEETS: MIHS), Pfizer Inc. (NYSE: PFE), Abbott (NYSE: ABT), Wyeth (NYSE: WYE). Medical Institutional Services Holdings, Inc (PINKSHEETS: MIHS) should havethe attention of investors this morning. Yesterday after the marketsclosed, the company, a wholesale distributor of medical supplies, issued...

  Articles 2008-04-18